A Phase 3 interventional study of iron sucrose in Chronic Kidney Disease, Chronic Heart Failure and Anemia, sponsored by Anemia Working Group Romania. Withdrawn at 2 sites in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-22.
Sponsored by Anemia Working Group Romania · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Renal Insufficiency, Chronic with a site in Romania — 8 open to participants now, 11 under way, 7 of them phase 3. Renal Insufficiency, Chronic · Romania.
Among the 65 studies in Renal Insufficiency, Chronic with a site in Romania, this one is the 55th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2008, is one of 40 in phase 3, and was the 2nd registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →8 of the 65 studies in Renal Insufficiency, Chronic with a site in Romania are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Romania, United States, Argentina and 24 more countries
Ages 18–99
AstraZeneca · Sites in Romania, United States, Argentina and 34 more countries
Ages 18+
Stefan Lujinschi · Sites in Romania
Ages 18+
Eli Lilly and Company · Sites in Romania, Argentina, Australia and 35 more countries
Ages 50+
AstraZeneca · Sites in Romania, United States, Argentina and 39 more countries
Ages 18+
A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 40 · Phase 4 4
First in 2004; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 455 across the 56 interventional studies, 200 across the 9 observational. Of the 50 that completed or were terminated, 34 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 65 have an industry lead sponsor. The 10 most frequent:
Anemia Working Group Romania is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Anemia Working Group Romania has 4 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Renal Insufficiency, Chronic with a site in Romania that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
| NCT07237451Grigore T. Popa University of Medicine and PharmacyCardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients | 2027-03-01 |
| NCT07697469Grigore T. Popa University of Medicine and PharmacyAtrial Cardiomyopathy in Patients With Cardiovascular-Kidney-Metabolic Syndrome: Non-invasive Characterization | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 65 studies in Renal Insufficiency, Chronic with a site in Romania, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recently, growing body of evidence support the finding that anemia frequently occurs in patients with chronic heart failure (CHF). Chronic kidney disease (CKD), as well, is highly prevalent among heart failure patients, and both anemia and CKD are independently associated with increased mortality. A vicious circle is established with CHF causing both chronic renal insufficiency and anemia, and CKD further aggravating anemia which, in turn, worsens CHF and so on. Treatment of the anemia breaks this circle and improves the quality of life, cardiac and renal functions in patients with severe CHF.
Intravenous iron alone was proved to allow the maintenance of target hematocrit in one-third of chronic renal failure predialysis patients.
Based on these considerations, intravenous iron for anemia in patients with CHF and moderate CKD would represent a reasonable therapeutic approach.
The aim of the trial is to assess the efficiency of intravenous iron therapy in the management of mild to moderate anemia associated with CHF NYHA III class and concomitant moderate CKD.
Intravenous iron administration in CHF patients with absolute or functional iron deficiency could correct their anemia, thus improving cardiac function judged by ejection fraction and NYHA functional class. If true, enhancement of cardiac output will increase oxygen delivery to tissues, including renal cortex. This might improve the renal functions and slow the rate of progression of CKD reflected by the slope of decline in glomerular filtration rate (GFR).
Since erythropoietin synthesis is located in peritubular fibroblasts from outer renal cortex, which is the most affected area during chronic hypoxia, increasing renal blood flow after anemia correction is expected to restore optimal erythropoietin production and normalize plasma Epo levels.
The primary objective is to assess the efficiency of intravenous iron therapy in the management of mild to moderate anemia associated with chronic heart failure NYHA III class and concomitant moderate chronic kidney disease.
The secondary objectives are to determine if the correction of anemia in these patients affects the cardiac function, the rate of progression of CKD and the plasma erythropoietin levels.
The study will be conducted in accordance with the Declaration from Helsinki and Tokyo, with the amendments from Venice (1983), after the approval by the local ethics committee.
The total observation period will be of 28 weeks, with a pre-study phase (selection, randomization of subjects) 4 weeks.The study period will last 24 weeks, with a possible extension to 48 weeks, depending on the results of this first phase.
200 anemic patients with chronic heart failure class NYHA III and concomitant stage 3 chronic kidney disease will be enrolled, after obtaining their written informed consent.
All patients will be evaluated for the inclusion and exclusion criteria at enrollment and at each visit during the pre-study phase. Only patients fulfilling all the requested criteria at all evaluation moments will be enrolled. The enrolled subjects will be centrally randomly assigned in a 1:1 ratio into two study groups.
Group I (treatment group): Subjects assigned to this group will receive intravenous iron (ferric sucrose product Venofer® 2%, 5mL/ampoule) in a starting dose of 200mg (2 ampoules) diluted in 150mL 0.9% NaCl solution, over 60 minutes, once a week for the first four administrations, and then every other week until hemoglobin levels reach 12g/dL. Then, iron dose will be adjusted to 1 ampoule at 2-4 weeks interval, as needed to maintain these levels with serum ferritin ≤500ng/mL.
Iron administration will be discontinued if serum ferritin will exceed 500ng/mL, and will be restarted with a reduced dosage (1 ampoule at every 2-4 weeks) once serum ferritin decrease below this value.
Conventional treatment for CHF will be continued as needed. Group II (control group): Subjects assigned to this group will continue their conventional treatment for CHF as needed, without iron supplementation.
No other anti-anemic medication will be administered in either group during the study period.
Subject's visits will take place at two weeks intervals in the first 12 weeks of the study phase and at 4 weeks apart thereafter. At each visit will be recorded, according to the schedule, data concerning physical examination, including signs of CHF, hematological and iron status, renal function, concomitant medication and adverse events.
Parameters recorded at the time of first iron administration will serve as baseline determination.
The completion of the study will be declared when 200 subjects will complete the whole observation period, according to the above protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
iv iron sucrose
Drug: iron sucrose
Patients will receive conventional treatment of Chronic Heart Failure.
Patients in Group I will receive iv iron sucrose, as described in the study protocol. Patient in Group II will receive conventional treatment for chronic heart failure.
Also known as: Group I - iv iron group, Group II - conventional treatment group
percentage of patients with increased ejection fraction
Time frame: 12 months
the need for blood transfusions during the study period
Time frame: 12 months
serum ferritin level
Time frame: 12 months
transferrin saturation
Time frame: 12 months
radial myocardial velocities
Time frame: 12 months
right ventricular function
Time frame: 12 months
global diastolic function
Time frame: 12 months
left ventricular mass index
Time frame: 12 months
major cardiovascular events (myocardial infarction, acute pulmonary edema, stroke)
Time frame: 12 months
hospital admissions
Time frame: 12 months
death of the patient (all causes deaths, cardiac deaths)
Time frame: 12 months
slope of GFR change
Time frame: 12 months
"death" of the kidney (initiation of renal replacement therapy)
Time frame: 12 months
Ran from Jan 2008 to primary completion in Dec 2017, 119 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron sucrose
Renal Insufficiency, Chronic →
Anemia Working Group Romania